Diabetic neuropathy in the XXXX : 1. Alcar augments the reduced levels and axoplasmic transport of substance P.

@entity1 @entity8580 @entity6 @entity5121 @entity16 @entity4162 @entity35 @entity734 @entity4854 @entity8371
This study examined the sciatic nerve axonal transport of @entity734 ( @entity734 ) and its basal content in stomach, sciatic nerve and lumbar spinal cord of 8- and 12-week alloxan- @entity6 @entity35 , respectively. One group of @entity6 @entity35 received @entity4162 (ALCAR) throughout the experimental period. Alloxan treatment caused @entity4854 and reduced @entity1 growth. Axonal transport of @entity734 was studied by measurement of 24-hour accumulation at a ligature on the sciatic nerve. There was a marked reduction (from 50% to 100% according to the nerve segment examined) of anterograde and retrograde accumulation of @entity734 in the constricted nerve of 8-week @entity6 @entity35 . In the sciatic nerve of ALCAR-treated @entity6 @entity35 , the accumulation of @entity734 was comparable to control values. In the sciatic nerve, lumbar spinal cord and stomach of 12-week @entity6 @entity35 , there is a significant reduction of @entity734 content. ALCAR treatment prevented @entity734 loss in these tissues. Sciatic nerves showed the typical @entity5121 increase and @entity8580 loss that were significantly counteracted by ALCAR. This study suggests that ALCAR treatment prevents @entity6 -induced @entity16 by improving altered metabolic pathways such as @entity8371 activity and @entity8580 synthesis, and by preventing the reduction of synthesis and axonal transport of substance P.
